Athira Pharma, Inc. (ATHA) Stock Analysis

Athira Pharma, Inc. (ATHA) Healthcare & Pipeline Overview

Athira Pharma, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative diseases, primarily Alzheimer's and Parkinson's. Their lead candidate, ATH-1017, is undergoing Phase 3 and Phase 2 clinical trials, positioning Athira in the competitive Alzheimer's treatment landscape with a focus on restoring neuronal health.

What Is the Investment Thesis for ATHA?

Athira Pharma operates in the high-risk, high-reward biotechnology sector, primarily focused on Alzheimer's disease. The investment thesis hinges on the successful completion of Phase 3 trials for ATH-1017 (LIFT-AD) with data expected to be released in the near future. Positive results could lead to accelerated regulatory approval and significant market uptake, given the unmet need in Alzheimer's treatment. Key value drivers include the potential for ATH-1017 to demonstrate disease-modifying effects, differentiating it from existing symptomatic treatments. The company's market capitalization of $26.6M reflects the inherent risks associated with clinical-stage biotech companies. Failure to achieve positive clinical trial outcomes or secure regulatory approval represents significant downside risks.

Based on FMP financials and quantitative analysis

ATHA Key Highlights

ATH-1017 is in Phase 3 clinical trials (LIFT-AD) for Alzheimer's disease, targeting a large and underserved patient population.

• ATH-1017 is a blood brain barrier-penetrating, small molecule HGF/MET positive modulator, potentially offering a novel mechanism of action.
• The company has preclinical programs (ATH-1019 and ATH-1020) targeting peripheral nervous system and neuropsychiatric conditions, diversifying its pipeline.
• Athira Pharma changed its name from M3 Biotechnology in April 2019, signaling a strategic shift and renewed focus.
• The company is headquartered in Bothell, Washington, a region with a strong biotechnology presence.

Who Are ATHA's Competitors?

ATHA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATHA's Key Strengths?

Novel approach to treating neurodegenerative diseases by restoring neuronal health.

• Lead product candidate, ATH-1017, in Phase 3 clinical trials.
• Experienced management team with expertise in drug development.
• Proprietary small molecule platform.

What Are ATHA's Weaknesses?

Limited financial resources.

• High dependence on the success of ATH-1017.
• Small number of employees (26).
• High beta of 2.80, indicating high volatility.

What Could Drive ATHA Stock Higher?

Data readout from the LIFT-AD Phase 3 clinical trial for ATH-1017 in Alzheimer's disease.

• Enrollment and progress in the ACT-AD Phase 2 clinical trial for ATH-1017 in Alzheimer's disease.
• Advancement of preclinical programs for ATH-1019 and ATH-1020.

What Are the Key Risks for ATHA?

Financial-distress signal — its Altman Z-Score of -13.39 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Regulatory delays or rejection of ATH-1017.
• Competition from other companies developing Alzheimer's treatments.
• Dependence on securing additional funding to support operations.
• Patent challenges to Athira's intellectual property.

What Are the Growth Opportunities for ATHA?

• Successful Completion of LIFT-AD Phase 3 Trial: The primary growth opportunity lies in the successful completion of the LIFT-AD Phase 3 clinical trial for ATH-1017 in Alzheimer's disease. Positive results, demonstrating statistically significant improvements in cognition and function, could lead to accelerated regulatory approval. The Alzheimer's disease market is estimated to reach $11.57 billion by 2029, presenting a substantial commercial opportunity for Athira if ATH-1017 proves effective. Timeline: Data readout expected in the near future.
• Advancement of Parkinson's Disease Program: Athira is also conducting Phase 2 clinical trials of ATH-1017 in Parkinson's disease. Positive data in this indication would expand the potential market for ATH-1017 and diversify the company's pipeline. The Parkinson's disease market is projected to reach $8.2 billion by 2030. A successful outcome could position Athira as a player in this significant market. Timeline: Ongoing Phase 2 trials.
• Development of ATH-1019 for Peripheral Nervous System Indications: Athira's preclinical program, ATH-1019, targets peripheral nervous system disorders. Successful preclinical development and subsequent clinical trials could open up a new therapeutic area for the company. The market for peripheral neuropathy treatment is expected to grow, driven by the increasing prevalence of diabetes and other risk factors. Timeline: Preclinical stage.
• Development of ATH-1020 for Neuropsychiatric Conditions: Athira is also developing ATH-1020 for neuropsychiatric conditions. This program represents a longer-term growth opportunity, as it is currently in the preclinical stage. The market for neuropsychiatric drugs is substantial, but also highly competitive. Timeline: Preclinical stage.
• Potential for Strategic Partnerships: Given its limited resources, Athira may seek strategic partnerships with larger pharmaceutical companies to support the development and commercialization of its product candidates. Such partnerships could provide access to funding, expertise, and global distribution networks, accelerating the company's growth. Timeline: Ongoing.

What Threats Does ATHA Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger pharmaceutical companies.
• Patent challenges.

What Are ATHA's Competitive Advantages?

• Proprietary small molecule therapeutics targeting neurodegenerative diseases.
• Patent protection for ATH-1017 and other product candidates.
• Clinical trial data demonstrating safety and efficacy.
• Expertise in HGF/MET pathway modulation.

What Does ATHA Do?

Athira Pharma, Inc., established in 2011 and headquartered in Bothell, Washington, is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. Originally named M3 Biotechnology, Inc., the company rebranded as Athira Pharma in April 2019 to reflect its evolved focus. The company's core mission centers around restoring neuronal health and slowing neurodegeneration through the development of small molecule therapeutics. Their lead product candidate, ATH-1017, is a blood-brain barrier penetrating molecule designed to positively modulate the HGF/MET pathway. This pathway is crucial for neuronal survival and function. ATH-1017 is currently undergoing Phase 3 (LIFT-AD) and Phase 2 (ACT-AD) clinical trials for Alzheimer's disease, as well as Phase 2 trials for Parkinson's disease. Beyond ATH-1017, Athira is also advancing preclinical programs, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions. Athira's strategy involves targeting the underlying mechanisms of neurodegeneration to provide disease-modifying treatments.

What Products and Services Does ATHA Offer?

• Develop small molecule therapeutics for neurodegenerative diseases.
• Focus on restoring neuronal health and slowing neurodegeneration.
• Advance ATH-1017, a HGF/MET positive modulator, through clinical trials.
• Target Alzheimer's disease and Parkinson's disease with ATH-1017.
• Develop preclinical programs for peripheral nervous system and neuropsychiatric conditions.
• Conduct Phase 3 clinical trials for ATH-1017 in Alzheimer's disease (LIFT-AD).

How Does ATHA Make Money?

• Develop and patent novel small molecule therapeutics.
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA and other agencies.
• Potentially commercialize products directly or through partnerships.

What Industry Does ATHA Operate In?

Athira Pharma operates within the biotechnology industry, specifically targeting the neurodegenerative disease market. This market is characterized by high unmet needs, particularly in Alzheimer's and Parkinson's diseases. The competitive landscape includes major pharmaceutical companies and smaller biotech firms, all vying to develop effective treatments. The industry is driven by an aging global population and increasing prevalence of neurodegenerative disorders. Success in this field requires significant investment in research and development, navigating complex regulatory pathways, and demonstrating clinical efficacy.

Who Are ATHA's Key Customers?

• Patients suffering from Alzheimer's disease.
• Patients suffering from Parkinson's disease.
• Healthcare providers who treat these patients.
• Potential pharmaceutical partners.

The most recent 3 insider filings for Athira Pharma, Inc. break down as 1 sales and 2 purchases. On net that is roughly 185 shares acquired (about $3K) — insiders putting money in tends to read as conviction.

Athira Pharma, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 611.7% below estimates on average.

Athira Pharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.39 places it in the distress zone, a signal of elevated financial risk.

Athira Pharma, Inc. (ATHA) Valuation Context

Valued at $26.6M, ATHA is classified as a micro-cap stock. Analyst price targets span from $3.00 to $33.00, with a consensus of $13.33. At the current price of $6.75, that implies approximately 97% upside potential.

ATHA Revenue & Earnings Trend

In Q2 FY2026, ATHA generated $0 in top-line revenue. The company recorded a net loss of $19.0M, with diluted EPS of $-0.80. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ATHA averaged $-5.90 in diluted EPS.

Company Profile

Athira Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bothell, US. The company is led by CEO Mark J. Litton. ATHA has traded publicly since 2020.

ATHA Financials

ATHA Latest News

ATHA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources